This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

Setting and Achieving Goals in IBD

SIMPONI Prescribing Information | REMICADE (infliximab) Prescribing Information

This video has been organised and fully funded by MSD.

Length: 22:20

Chapters
00:00 Introduction to STRIDE
08:53 Potential value of treat-to-target strategies in IBD
15:28 Conclusions and recommendations

The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) program examined potential treatment targets for inflammatory bowel disease (IBD) to be used for a "treat-to-target" clinical management strategy.

In this video, Dr. Mark Samaan discusses the reasons behind the initiation of the STRIDE program, the potential value of treat-to-target strategy in IBD and his overall conclusions and recommendations.

Dr. Mark Samaan Image

Dr. Mark Samaan

Dr. Mark Samaan is currently a Clinical Research Fellow at Guy's and St Thomas' NHS Trust, investigating therapeutic drug monitoring for biologic agents in IBD, as part of an MD program at King's College.

More information about SIMPONI® (golimumab):